MNKD
MNKD clinical trials: MANNKIND CORP
Every trial on ClinicalTrials.gov where MANNKIND CORP is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 64
- Trials linked
- 57
- As lead sponsor
- 7
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
MNKD on the catalyst calendar · MNKD registry changes
- Primary completion Dec 30, 2027Sponsor estimatePhase 2NCT07679893Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary FibrosisMannkind Corporation · Idiopathic Pulmonary FibrosisRecruitingMNKDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2027Sponsor estimatePhase 2NCT07224321INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 DiabetesMannkind Corporation · Type 1 Diabetes MellitusRecruitingMNKDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 17, 2026ActualPhase 1NCT07344558A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary FibrosisMannkind Corporation · Idiopathic Pulmonary Fibrosis (IPF)CompletedMNKDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 10, 2025ActualPhase 3NCT06418711ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation SuspensionMannkind Corporation · MAC Lung DiseaseTerminatedMNKDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 3, 2024ActualPhase 3NCT04974528Afrezza® INHALE-1 Study in PediatricsMannkind Corporation · Diabetes Mellitus, Type 1CompletedMNKDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 17, 2022ActualPhase 4NCT05243628Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 DiabetesMannkind Corporation · Type 1 DiabetesCompletedMNKDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 26, 2024ActualPhase 4NCT05904743INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 DiabetesMannkind Corporation · Diabetes Mellitus, Type 1CompletedMNKDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 31, 2024Sponsor estimatePhase 1NCT06532942A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MKND-201 in Healthy VolunteersMannkind Corporation · Healthy VolunteersUnknown statusMNKDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 28, 2021ActualPhase 4NCT04849845Afrezza® Dosing Optimization StudyMannkind Corporation · Diabetes Mellitus, Type 1CompletedMNKDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 17, 2020ActualPhase 2NCT02527265Afrezza Safety and Pharmacokinetics Study in Pediatric PatientsMannkind Corporation · Type 1 Diabetes MellitusCompletedMNKDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 5, 2018ActualPhase 1NCT03464864Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal VolunteersMannkind Corporation · Pulmonary Arterial HypertensionCompletedMNKDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2015ActualPhase 1NCT02470637Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of...Mannkind Corporation · Type 1 Diabetes MellitusCompletedMNKDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2014ActualPhase 3NCT00642616Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary DiseaseMannkind Corporation · Type 1 Diabetes MellitusTerminatedMNKDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2015ActualPhase 1NCT02485327PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1...Mannkind Corporation · Type 1 Diabetes MellitusCompletedMNKDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2015ActualNo phase registeredNCT01798914Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation PowderMannkind Corporation · Type 1 DiabetesNo longer availableMNKDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2013ActualPhase 1NCT01902121Compare the Same Dosage of Insulin Using a Combination of Cartridges, 30 Units as 2 Cartridges vs. 1 CartridgeMannkind Corporation · Healthy VolunteersCompletedMNKDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2008ActualNo phase registeredNCT00741429A 2-Month Safety Follow-Up TrialMannkind Corporation · Type 1 DiabetesCompletedMNKDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2008ActualNo phase registeredNCT00642681Effects of URI on Diabetic Subjects Utilizing Technosphere Insulin After a Meal ChallengeMannkind Corporation · Diabetes MellitusCompletedMNKDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2011ActualPhase 3NCT01196104Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 InhalerMannkind Corporation · Type 2 DiabetesTerminatedMNKDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2011ActualPhase 2NCT00747006Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied...Mannkind Corporation · Diabetes Mellitus, Type 2TerminatedMNKDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2013ActualPhase 3NCT01445951Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment...Mannkind Corporation · Type 1 Diabetes MellitusCompletedMNKDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2013ActualPhase 3NCT01451398Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes MellitusMannkind Corporation · Type 2 DiabetesCompletedMNKDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2008ActualPhase 2NCT00754624An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' TrialMannkind Corporation · Type 2 Diabetes MellitusCompletedMNKDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2009ActualPhase 3NCT00700622Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-WeeksMannkind Corporation · Diabetes, Type 1TerminatedMNKDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2008ActualPhase 2NCT00662857A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those...Mannkind Corporation · Diabetes Mellitus: Type 1CompletedMNKDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 39 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner